Changes in Plasma Leptin Levels in Men in Response to Aerobic Training, and Using Orlistat

Document Type : Original Article (s)

Authors

1 PhD Student, Department of Exercise Physiology, School of Physical Education, Guilan University, Rasht, Iran

2 Professor, Department of Exercise Physiology, School of Physical Education, Guilan University, Rasht, Iran

3 Associate Professor, Department of Internal Medicine, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

Abstract

Background: Obesity is a complex disorder with excessive accumulation of adipose tissue; the tissue that exudes leptin, a hormone which plays an important role in the regulation of cellular metabolism and energy balance. The purpose of this study was to determine the changes in plasma leptin levels in response to aerobic training, and using orlistat in men.Methods: Forty-eight obese males with a mean age of 21.56 ± 2.14 years and a mean body mass index (BMI) of 33.90 ± 3.21 kg/m2 participated in this study. The subjects were divided into four equal groups (n = 12) of orlistat, exercise, and orlistat-plus-exercise-induced weight loss, and control. Subjects of orlistat and orlistat plus exercise groups received 120 mg orlistat capsules three times daily after each meal for eight weeks. Aerobic training program consisted of running for 55 to 60 percent of target heart rate for 25 minutes on a treadmill in first week, and then, 75 percent of target heart rate for 45 minutes for the seven week. The levels of plasma leptin were measured using the enzyme-linked immunosorbent assay (ELISA) method before and after intervention.Findings: All three experimental groups showed significant decreases in plasma levels of leptin compared to control group and before intervention (P = 0.001).Conclusion: The results show that aerobic exercise can reduce plasma leptin levels in obese people. The results show that regular aerobic exercise without the use of chemical drugs lead to weight loss with desirable changes in serum leptin levels.

Keywords

References

  1. Gippini A, Mato A, Peino R, Lage M, Dieguez C, Casanueva FF. Effect of resistance exercise (body building) training on serum leptin levels in young men. Implications for relationship between body mass index and serum leptin. J Endocrinol Invest 1999; 22(11): 824-8.
  2. Ordonez FJ, Fornieles-Gonzalez G, Camacho A, Rosety MA, Rosety I, Diaz AJ, et al. Anti-inflammatory effect of exercise, via reduced leptin levels, in obese women with Down syndrome. Int J Sport Nutr Exerc Metab 2013; 23(3): 239-44.
  3. Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mikhailidis DP. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets 2010; 11(1): 122-35.
  4. Dyson PA. The therapeutics of lifestyle management on obesity. Diabetes Obes Metab 2010; 12(11): 941-6.
  5. Carrasco NF, Manrique M, de la Maza MP, Moreno M, Albala C, Garcia J, et al. Statement about the medical and surgical treatment of overweight and obesity. Rev Med Chil 2009; 137(7): 972-81. [In Spanish].
  6. Elmahgoub SS, Calders P, Lambers S, Stegen SM, Van LC, Cambier DC. The effect of combined exercise training in adolescents who are overweight or obese with intellectual disability: the role of training frequency. J Strength Cond Res 2011; 25(8): 2274-82.
  7. Shalaby HMA, Tawfek NS, Abo-El Hussein BK, El-Ghany MSEMA. The assessment of some biochemical and immunological effects by amphetamine and orlistat on obesity in rats. Food and Public Health 2014; 4(4): 185-92.
  8. Dolenc A, Govedarica B, Dreu R, Kocbek P, Srcic S, Kristl J. Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition. Int J Pharm 2010; 396(1-2): 149-55.
  9. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21(8): 1288-94.
  10. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8(1): 49-61.
  11. Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord 2003; 27(5): 591-7.
  12. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol. 1999; 39(1): 41-6.
  13. Kang JG, Park CY. Anti-obesity drugs: A review about their effects and safety. Diabetes Metab J 2012; 36(1): 13-25.
  14. Rump P, Verstappen F, Gerver WJ, Hornstra G. Body composition and cardiorespiratory fitness indicators in prepubescent boys and girls. Int J Sports Med 2002; 23(1): 50-4.
  15. Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens) 2006; 5(4): 259-69.
  16. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10(7): 642-50.
  17. Ozcelik O, Dogan H, Celik H, Ayar A, Serhatlioglu S, Kelestimur H. Effects of different weight loss protocols on serum leptin levels in obese females. Physiol Res 2005; 54(3): 271-7.
  18. Gueugnon C, Mougin F, Nguyen NU, Bouhaddi M, Nicolet-Guenat M, Dumoulin G. Ghrelin and PYY levels in adolescents with severe obesity: effects of weight loss induced by long-term exercise training and modified food habits. Eur J Appl Physiol 2012; 112(5): 1797-805.
  19. de Winter CF, Bastiaanse LP, Hilgenkamp TI, Evenhuis HM, Echteld MA. Overweight and obesity in older people with intellectual disability. Res Dev Disabil 2012; 33(2): 398-405.
  20. Mager U, Kolehmainen M, de Mello VD, Schwab U, Laaksonen DE, Rauramaa R, et al. Expression of ghrelin gene in peripheral blood mononuclear cells and plasma ghrelin concentrations in patients with metabolic syndrome. Eur J Endocrinol 2008; 158(4): 499-510.
  21. Kelishadi R, Hashemipour M, Mohammadifard N, Alikhassy H, Adeli K. Short- and long-term relationships of serum ghrelin with changes in body composition and the metabolic syndrome in prepubescent obese children following two different weight loss programmes. Clinical Endocrinology 2008; 69(5): 721-9.
  22. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20(9): 1873-8.
  23. Christiansen T, Paulsen SK, Bruun JM, Pedersen SB, Richelsen B. Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: a 12-week randomized intervention study. Am J Physiol Endocrinol Metab 2010; 298(4): E824-E831.
  24. Tenenbaum A, Chavkin M, Wexler ID, Korem M, Merrick J. Morbidity and hospitalizations of adults with Down syndrome. Res Dev Disabil 2012; 33(2): 435-41.
  25. Palacios-Martinez D, Garcia-Alvarez JC, Montero-Santamaria N, Villar-Ruiz OP, Ruiz-Garcia A, Diaz-Alonso RA. Macrocytic anemia and thrombocytopenia induced by orlistat. Int J Endocrinol Metab 2013; 11(4): e6721.
  26. Verma SK, Vaish AK. Effect of Orlistat on blood pressure in overweight/obese hypertensive patients. OSR Journal of Dental and Medical Sciences 2014; 13(8): 67-70.
  27. Thamer SJ. the effect of orlistat and metformin treatment on body weight, liver steatsis, leptin and insulin sensitivity in obese rats fed high fat diet. J Am Sci 2014; 10(4): 107-14.
  28. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31(1): 53-65.
  29. Ahmad FA, Mahmud S. Acute pancreatitis following orlistat therapy: report of two cases. JOP 2010; 11(1): 61-3.
  30. Reseland JE, Anderssen SA, Solvoll K, Hjermann I, Urdal P, Holme I, et al. Effect of long-term changes in diet and exercise on plasma leptin concentrations. Am J Clin Nutr 2001; 73(2): 240-5.
Journal of Isfahan Medical School
Volume 35, Issue 419 - Serial Number 419
January and February 2017
Pages 111-118

Files

History

  • Receive Date: 01 November 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics